MyFinsight
Home
Blog
About
Contact
Download
Download image
Cash and cash
equivalents
$31,976,000
Inventory, net
$23,418,000
Accounts receivable, net
$11,700,000
Prepaid expenses and
other current assets
$2,457,000
Restricted cash, current
$250,000
2031 and thereafter
$19,495,000
2027
$4,175,000
2028
$3,975,000
2029
$3,830,000
2030
$3,822,000
2026 (april 1 -
december 31)
$3,143,000
Total current assets
$69,801,000
Intangible assets, net
$38,440,000
Goodwill
$24,681,000
Property and equipment,
net
$9,310,000
Operating lease
right-of-use assets, net
$3,146,000
Total assets
$145,378,000
Total liabilities and
stockholders' equity
$145,378,000
Total liabilities
$110,276,000
Total stockholders'
equity
$35,102,000
Accumulated deficit
-$75,032,000
Other long-term
liabilities
$31,955,000
Venture loan and
security agreement, net
$26,356,000
Total current
liabilities
$25,003,000
Convertible debt
$23,283,000
Operating lease
liabilities, net of current...
$2,652,000
Deferred revenue, net of
current portion
$1,027,000
Additional paid in capital
$106,945,000
Accumulated other
comprehensive income
$3,189,000
Accrued expenses
$12,835,000
Accounts payable
$6,147,000
Other liabilities
$3,403,000
Contingent consideration
$1,000,000
Deferred revenue,
current portion
$978,000
Operating lease
liabilities, current portion
$640,000
Back
Back
Balance Sheet
source: myfinsight.com
Pelthos Therapeutics Inc. (PTHS)
Pelthos Therapeutics Inc. (PTHS)